Dec 13 -- Artificial heart-maker Carmat is 'rather confident' on the resumption of implants in the final-stage clinical trial for its artificial hearts, its chief executive Stephane Piat said on Tuesday.
France's national drugs agency, ANSM, ordered Carmat to suspend further implants earlier this month following the death of a patient in October.
"In the light of the data we collected with the fifth patient, the data are very encouraging," Piat said on French radio BFM Business. "That's why I am rather confident today," he added, concerning the resumption of the clinical trial program.
France's national drugs agency, ANSM, ordered Carmat to suspend further implants earlier this month following the death of a patient in October.
"In the light of the data we collected with the fifth patient, the data are very encouraging," Piat said on French radio BFM Business. "That's why I am rather confident today," he added, concerning the resumption of the clinical trial program.
